Trial Profile
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Sep 2021 Planned End Date changed from 13 Jun 2020 to 30 Jun 2024.
- 24 Sep 2021 Planned primary completion date changed from 13 Jun 2020 to 30 Jun 2024.
- 17 Jul 2019 Planned End Date changed from 1 Jul 2019 to 13 Jun 2020.